| 摘要: |
| 动脉粥样硬化是许多心血管疾病的早期病理改变,脂质代谢紊乱是动脉粥样硬化性心血管疾病(ASCVD)最重要的危险因素之一。前蛋白转化酶枯草杆菌蛋白酶/kexin 9 型 (PCSK9) 是血脂调节的关键因子,可以通过与低密度脂蛋白受体(LDLR)结合,降解LDLR从而阻止低密度脂蛋白的清除,导致低密度脂蛋白胆固醇(LDL-C)水平升高,增加心血管疾病的风险。PCSK9也参与炎症细胞因子的生成、内皮功能障碍和动脉粥样硬化斑块的形成。多项研究显示,PCSK9是治疗ASCVD的一个有希望的新靶点。PCSK9抑制剂是目前治疗高胆固醇血症的新型药物。本文就PCSK9抑制剂在动脉粥样硬化中的作用及药物研究进展做一综述,为临床用药提供参考。 |
| 关键词: 前蛋白转化酶枯草杆菌蛋白酶/kexin9型抑制剂 动脉粥样硬化 人前蛋白转化酶枯草溶菌素9 动脉粥样硬化性心血管疾病 胆固醇 低密度脂蛋白胆固醇 |
| DOI:10.13506/j.cnki.jpr.2024.05.013 |
| 基金项目:山东省高等学校科技计划项目(No.J15LM58) |
|
出版日期:2024-05-25
|
|
| Research Status of New lipid-lowering Drugs PCSK9 Inhibitors in Arteriosclerosis Cardiovascular Disease |
| ME Guowen1,2,LIU Shichang3,WANG Hailiang2,JIANG Wenyan1,WANG Xuejian1 |
| (1.College of Pharmacy, Weifang Medical College, Weifang 261053, China;2.Weifang People’s Hospital, Weifang 261041, China;3.Weifang Mental Health Center, Weifang 261072, China) |
| Abstract: |
| Atherosclerosis is an early pathological change of many cardiovascular diseases. Lipid metabolism disorder is one of the most important risk factors of atherosclerotic cardiovascular disease (ASCVD). Proprotein conver-tase subtilisin/kexin type 9 (PCSK9) is a key protein in lipid metabolism. It can bind to low-density lipoprotein receptor (LDLR) and degrade LDLR to prevent the clearance of low-density lipoprotein, resulting in increased Low density lipoprotein cholesterol (LDL-C) levels. Increased risk of cardiovascular disease. PCSK9 is also involved in the production of inflammatory cytokines, endothelial dysfunction and the formation of atherosclerotic plaques. A number of studies have shown that PCSK9 is a promising new target for the treatment of ASCVD.PCSK9 inhibitors are currently a new type of drug for the treatment of hypercholesterolemia. This article reviews the role of PCSK9 inhibitors in atherosclerosis and the research progress of drugs, so as to provide reference for clinical medication. |
| Key words: Proprotein convertase 9 inhibitors Atherosclerosis Human proprotein convertase subtilisin/kexin type 9 inhibitor ASCVD Cholesterol Low-density lipoprotein cholesterol |